Meissa Vaccines: Marty Moore, Founder And Chief Executive Officer
Meissa Vaccines is a pharmaceutical start-up company focused on advancement of unmet vaccines against viruses that cause serious human diseases, such as respiratory syncytial
BioGraph 55, Inc: Paul Tumeh, Co-founder and CEO
BioGraph 55, Inc. is a San Francisco based early-stage target discovery and drug development biotech company focused on immuno-oncology. The company leverages a proprietary and scientifically validated (through external partners) spatial-mapping technology platform called SPARTA (Spatial Processing And Regional Tissue Analysis) that collects biological information from cellular interactions in their native environment and integrates this information with genomic and transcriptomic data to identify new drug targets. The first program aims to develop an antibody therapy that i) targets refractory, “hot” solid tumors, ii) removes local immunosuppression from “hot” tumors and iii) uses a biomarker assay to identify patients likely to benefit from monotherapy.
Inflammatix:Tim Sweeney, CEO
Inflammatix is a molecular diagnostics company developing rapid tests that read the immune system to resolve major clinical and public health challenges. We are initially focused on developing tests for acute bacterial and viral infections, and sepsis based on patent-pending biomarkers exclusively licensed from Stanford University. Beyond this initial focus, our expert bioinformatics and assay development teams are poised to build a host response-based diagnostics pipeline that includes tests for tropical infections, autoimmune diseases, transplant rejection and other conditions.